Recall Record

Levittown, PA, United States

Torrent Pharma Inc recalls

14 recalls recorded since 2018, most recently on 27 May 2025. 5 are listed as ongoing. Status and classification are as published by the FDA.

Recalls14
Ongoing (FDA)5
Terminated or completed9
Class I (FDA)1

Completed Class II Drugs

Recall started
27 May 2025
Reason
CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.
Distribution
U.S. Nationwide.
Initiated
Voluntary: Firm initiated
Recall numbers
D-0456-2025, D-0455-2025

Terminated Class II Drugs

Recall started
11 April 2022
Terminated
25 July 2023
Reason
CGMP deviations: tablets cracking
Distribution
Nationwide in the U.S.A
Initiated
Voluntary: Firm initiated
Recall number
D-0852-2022

Terminated Class II Drugs

Recall started
2 December 2021
Terminated
23 October 2023
Reason
Failed Dissolution Specifications
Distribution
Nationwide USA
Initiated
Voluntary: Firm initiated
Recall number
D-0365-2022

Terminated Class III Drugs

Recall started
1 December 2021
Terminated
12 May 2024
Reason
Superpotent; Hydrochlorothiazide
Distribution
Nationwide USA
Initiated
Voluntary: Firm initiated
Recall number
D-0285-2022

Terminated Class I Drugs

Recall started
25 November 2020
Terminated
28 December 2022
Reason
Failed Dissolution Specifications
Distribution
Nationwide USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall number
D-0166-2021

Terminated Class II Drugs

Recall started
11 May 2020
Terminated
10 August 2022
Reason
Failed Dissolution Specifications
Distribution
USA Nationwide and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall number
D-1317-2020

Ongoing Class II Drugs

Recall started
19 September 2019
Reason
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.
Distribution
Nationwide USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall numbers
D-0124-2020, D-0123-2020, D-0121-2020, D-0122-2020

Terminated Class II Drugs

Recall started
6 September 2019
Terminated
3 November 2020
Reason
Failed Impurities/Degradation Specifications: High Out Of Specification results for impurities detected during routine stability testing.
Distribution
Nationwide in the USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall number
D-1862-2019

Terminated Class II Drugs

Recall started
21 May 2019
Terminated
6 October 2020
Reason
cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).
Distribution
Product was distributed to 9 distributors, direct accounts and relabelers who may have further distributed the product throughout the United States.
Initiated
Voluntary: Firm initiated
Recall numbers
D-1371-2019, D-1367-2019, D-1375-2019, D-1359-2019, D-1369-2019, D-1373-2019, D-1378-2019, D-1346-2019, D-1368-2019, D-1352-2019, D-1383-2019, D-1382-2019 and 29 more

Ongoing Class II Drugs

Recall started
18 April 2019
Reason
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.
Distribution
Nationwide USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall numbers
D-1266-2019, D-1264-2019, D-1267-2019, D-1269-2019, D-1265-2019, D-1268-2019

Ongoing Class II Drugs

Recall started
28 February 2019
Reason
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.
Distribution
Nationwide USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall numbers
D-1118-2019, D-1119-2019, D-1116-2019, D-1115-2019, D-1114-2019, D-1117-2019

Ongoing Class II Drugs

Recall started
20 December 2018
Reason
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.
Distribution
Nationwide USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall numbers
D-0503-2019, D-0501-2019, D-0504-2019, D-0505-2019, D-0502-2019

Terminated Class II Drugs

Recall started
11 September 2018
Terminated
4 September 2020
Reason
Failed Dissolution Specifications: Out of Specification for Dissolution test (Buffer Stage) at the 5-hour time point during stability testing.
Distribution
Nationwide USA
Initiated
Voluntary: Firm initiated
Recall number
D-1204-2018

Ongoing Class II Drugs

Recall started
17 August 2018
Reason
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Distribution
Nationwide USA
Initiated
Voluntary: Firm initiated
Recall numbers
D-1138-2018, D-1145-2018, D-1137-2018, D-1135-2018, D-1142-2018, D-1140-2018, D-1136-2018, D-1134-2018, D-1141-2018, D-1139-2018, D-1144-2018, D-1143-2018

A terminated FDA recall means the FDA has determined that all reasonable efforts to remove or correct the product have been made. What statuses mean.